Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca RatonBOCA RATON, Fla. and VIENNA, Austria, March...
Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital...
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue...
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on...
Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization Management to host Investor Day...
BOCA RATON, Fla., March 24, 2023 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted...
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured...
BOSTON, March 24, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis,...
-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in...
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customersSOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) --...
- Program developments throughout 2022, and, to date in 2023, bring Grace Breeding closer to offering crop solutions to farmers aligned...
SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...
TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023Phase 2 proof-of-concept trial of farudodstat...
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living...
Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company")...
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24,...
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment,...
Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss...